Fredun Pharmaceuticals Acquires Furlicks From USV and Wellbeing Nutrition
Fredun Pharmaceuticals Acquires Furlicks
Business & Markets News
Fredun Pharmaceuticals Limited has acquired Furlicks, an innovative pet-wellness brand that focuses on oral-strip products designed to make pet care more convenient. The company said the acquisition brings Furlicks' product innovation and consumer understanding into the FPL Group.
The acquisition also gives Fredun Pharmaceuticals an opportunity to use its existing capabilities in manufacturing, product development, quality systems, R&D, supply chain and distribution to expand the pet-care business.
Fredun Pharmaceuticals Furlicks Acquisition Details
Furlicks has been acquired from Pharma Major USV and its subsidiary Wellbeing Nutrition.
The brand's portfolio includes products for skin and coat, gut health, joint care, calming, oral care and multivitamins.
The acquisition marks Fredun Pharmaceuticals' entry into India's high-growth pet-wellness market.
Strategic Focus of the Furlicks Acquisition
Fredun Pharmaceuticals plans to build on Furlicks' existing product portfolio while using its own manufacturing, R&D, product development and distribution capabilities.
The company highlighted the growing focus among pet parents on preventive health, nutrition and specialised products for pets. Furlicks' oral-strip format is positioned as an alternative to conventional forms of pet supplements.
Fredun Pharmaceuticals Furlicks Expansion Plans
The immediate focus will be on expanding Furlicks' existing business through new product launches. Fredun Pharmaceuticals plans to introduce 12 new SKUs in the first phase, while 32 additional SKUs are aligned for the second phase.
Over the longer term, the company aims to develop Furlicks from an oral-strip-focused brand into a broader everyday pet-wellness platform.
Fredun Pharmaceuticals Furlicks Acquisition Highlights
| Acquiring Company | Fredun Pharmaceuticals Limited |
|---|---|
| Acquired Brand | Furlicks |
| Acquired From | USV and its subsidiary Wellbeing Nutrition |
| Business Segment | Pet Wellness |
| Product Format | Oral strips |
| Key Categories | Skin and coat, gut health, joint care, calming, oral care and multivitamins |
| First-Phase Expansion | 12 new SKUs |
| Second-Phase Expansion | 32 new SKUs |
| Strategic Objective | Expand Furlicks into a broader everyday pet-wellness platform |
What to Watch Next
- Investors may track the rollout of the 12 new SKUs planned in the first phase.
- They can monitor the launch of the additional 32 SKUs planned for the second phase.
- Investors may also watch how Fredun Pharmaceuticals uses...
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Bajaj Nivesh Reports 9.7% Revenue Growth in Q2 FY27, Net Profit Rises 9.8%
Bajaj Nivesh Limited has reported its financial results for the quarter and half year ended September 30, 2026. The company recorded revenue from operations of Rs.297.36 crore in Q2 FY27, up 9.7% year-on-year (YoY). Net profit for the quarter stood at Rs.293.27 crore, while earnings per share increased to Rs.256.61 from Rs.233.69 in the corresponding quarter last year.
Balkrishna Industries Signs Strategic Partnership with Pirelli for Premium Car Tyres in India
Balkrishna Industries Limited (BKT) has signed a strategic agreement with Pirelli to expand its presence in India's premium passenger car tyre market. Under the agreement, BKT will produce up to 800,000 Pirelli-branded premium car tyres by 2030. Production will take place at one of BKT's newly constructed plants, equipped with advanced technology and designed to meet Pirelli's quality standards. The agreement also provides for a potential 50-50 joint venture to build a new production plant for high-value car tyres for domestic and international markets. The partnership aims to help both companies benefit from the expected growth in India's premium car tyre market.
Corona Remedies Receives ANVISA GMP Certification for Two Manufacturing Facilities
Corona Remedies Limited has received Good Manufacturing Practice (GMP) Compliance Certification from Brazil’s Health Regulatory Agency, ANVISA, for its Oral Solid Dosage (OSD) manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad, Gujarat. The company disclosed the development to BSE Limited and the National Stock Exchange of India Limited on October 22, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The certification may support the company's efforts to expand its presence in international pharmaceutical markets, subject to applicable regulatory requirements.